Epidemiology and Outcomes of Complicated Skin and Soft Tissue Infections among Inpatients in Southern China from 2008 to 2013.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
    • Publication Information:
      Original Publication: San Francisco, CA : Public Library of Science
    • Subject Terms:
      Anti-Bacterial Agents/*therapeutic use ; Skin Diseases, Bacterial/*drug therapy ; Skin Diseases, Bacterial/*economics ; Skin Diseases, Bacterial/*epidemiology ; Soft Tissue Infections/*epidemiology; Aged ; China/epidemiology ; Cost of Illness ; Drug Resistance, Multiple, Bacterial ; Escherichia coli/drug effects ; Female ; Hospitalization/economics ; Humans ; Inpatients ; Klebsiella pneumoniae/drug effects ; Length of Stay/economics ; Male ; Middle Aged ; Retrospective Studies ; Soft Tissue Infections/drug therapy ; Soft Tissue Infections/economics ; Staphylococcus aureus/drug effects ; Treatment Outcome
    • Abstract:
      Complicated skin and soft tissue infections (cSSTI) are some of the most commonly treated infections in hospitals, and place heavy economic burdens on patients and society. Here we report the findings from an analysis of cSSTI based on a retrospective study which was conducted within the Chinese inpatient population. We focused our research on the analysis of the patient population, antibiotic treatment, clinical outcome and economic burden. The study population comprised 527 selected patients hospitalized between 2008 and 2013. Among the hospitalizations with microbiological diagnoses, 61.41% (n = 113) were diagnosed as infected with Gram-positive bacteria, while 46.20% (n = 85) were infected with Gram-negative bacteria. The most commonly found Gram-positive bacteria was Staphylococcus aureus (40.76%, n = 75), and the most common Gram-negative bacteria was Escherichia coli (14.13%, n = 26). About 20% of the Staphylococcus aureus were methicillin-resistant. The resistance rate of isolated Staphylococcus aureus or Escherichia coli to penicillin was around 90%; in contrast, the resistance rate to vancomycin, linezolid or imipenem was low (<20%). A large percentage of patients were treated with cephalosporins and fluoroquinolones, while vancomycin and imipenem were also included to treat drug-resistant pathogens. Over half of the hospitalizations (58.43%, n = 336) experienced treatment modifications. The cost to patients with antibiotic modifications was relatively higher than to those without. In conclusion, our study offers an analysis of the disease characteristics, microbiological diagnoses, treatment patterns and clinical outcomes of cSSTI in four hospitals in Guangdong Province, and sheds lights on the current clinical management of cSSTI in China.
    • References:
      Surg Infect (Larchmt). 2009 Oct;10(5):467-99. (PMID: 19860574)
      J Med Econ. 2014 Oct;17(10):719-29. (PMID: 24983206)
      Antimicrob Agents Chemother. 2013 Jan;57(1):559-68. (PMID: 23147738)
      Diagn Microbiol Infect Dis. 2014 Mar;78(3):295-301. (PMID: 24359932)
      Int J Antimicrob Agents. 2008 Sep;32(3):241-9. (PMID: 18635341)
      Infect Control Hosp Epidemiol. 2009 Dec;30(12):1203-10. (PMID: 19848604)
      Springerplus. 2013 Dec 30;2:696. (PMID: 24422184)
      J Microbiol Immunol Infect. 2012 Feb;45(1):52-7. (PMID: 22153759)
      Clin Microbiol Infect. 2014 Apr;20 Suppl 4:3-18. (PMID: 24580738)
      Surg Infect (Larchmt). 2005 Fall;6(3):283-95. (PMID: 16201938)
      J Antimicrob Chemother. 2013 Jul;68 Suppl 2:ii45-55. (PMID: 23772046)
      BMC Infect Dis. 2014;14:476. (PMID: 25182029)
      Clin Infect Dis. 2005 Nov 15;41(10):1373-406. (PMID: 16231249)
      J Antimicrob Chemother. 1999 Sep;44 Suppl A:19-23. (PMID: 10511393)
      Int J Antimicrob Agents. 2013 Apr;41(4):372-8. (PMID: 23499225)
      Clin Infect Dis. 2011 Jul 15;53(2):144-9. (PMID: 21690621)
      Clin Microbiol Infect. 2013 Sep;19(9):E377-85. (PMID: 23663184)
      Expert Opin Pharmacother. 2008 Apr;9(5):717-30. (PMID: 18345950)
      J Microbiol Immunol Infect. 2011 Apr;44(2):116-24. (PMID: 21439514)
      Cleve Clin J Med. 2012 Jan;79(1):57-66. (PMID: 22219235)
      Diagn Microbiol Infect Dis. 2014 Jun;79(2):273-9. (PMID: 24661685)
      Cleve Clin J Med. 2007 Aug;74 Suppl 4:S21-8. (PMID: 17847175)
      Expert Opin Pharmacother. 2014 Jul;15(10):1351-70. (PMID: 24766095)
      J Clin Microbiol. 2012 Feb;50(2):238-45. (PMID: 22116149)
    • Accession Number:
      0 (Anti-Bacterial Agents)
    • Publication Date:
      Date Created: 20160227 Date Completed: 20160808 Latest Revision: 20181113
    • Publication Date:
      20240104
    • Accession Number:
      PMC4769280
    • Accession Number:
      10.1371/journal.pone.0149960
    • Accession Number:
      26918456